{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:09:02Z","timestamp":1740107342283,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Progressive supranuclear palsy (PSP) is a rare and fatal neurodegenerative movement disorder with no disease modifying therapy currently available. Data on the costs associated with PSP are scarce. This study aims to assess the direct medical expenditure of patients with PSP (PwPSP) throughout disease course.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study is based on the data of a large state-mandated health provider in Israel. We identified PwPSP who were initially diagnosed between 2000 and 2017. Each PwPSP was randomly matched to three health-plan members without PSP by birth-year, sex, and socioeconomic status. Healthcare resources\u2019 utilization and related costs were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 88 eligible PwPSP and 264 people in the reference group; mean age at diagnosis was 72.6\u00a0years (SD\u2009=\u20098.4) and 53.4% were female. The annual direct costs of PwPSP have risen over time, reaching US$ 21,637 in the fifth year and US$ 36,693 in the tenth year of follow-up vs US$ 8910 in the year prior diagnosis. Compared to people without PSP, PwPSP had substantially higher medical expenditure during the years prior- and post-index date.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The present study demonstrates higher economic burden, which increases with time, in PwPSP as compared to those without.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-023-11714-1","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T18:02:10Z","timestamp":1681754530000},"page":"3770-3778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Progressive supranuclear palsy\u2019s economical burden: the use and costs of healthcare resources in a large health provider in Israel"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3264-3380","authenticated-orcid":false,"given":"Yael","family":"Barer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raanan","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meital","family":"Grabarnik-John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Zamudio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Gurevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"issue":"18","key":"11714_CR1","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0000000000002638","volume":"86","author":"IT Coyle-Gilchrist","year":"2016","unstructured":"Coyle-Gilchrist IT, Dick KM, Patterson K, Rodr\u00edquez PV, Wehmann E, Wilcox A et al (2016) Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 86(18):1736\u20131743","journal-title":"Neurology"},{"key":"11714_CR2","doi-asserted-by":"publisher","first-page":"S750","DOI":"10.1016\/j.jval.2019.09.1844","volume":"22","author":"A Scowcroft","year":"2019","unstructured":"Scowcroft A, Thompson A (2019) PND74 prevalence of progressive supranuclear palsy (PSP) in Europe, Japan and the USA. Value in Health 22:S750","journal-title":"Value in Health"},{"issue":"3","key":"11714_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","volume":"8","author":"DR Williams","year":"2009","unstructured":"Williams DR, Lees AJ (2009) Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 8(3):270\u2013279","journal-title":"Lancet Neurol"},{"issue":"9","key":"11714_CR4","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/brainsci12091126","volume":"12","author":"Y Barer","year":"2022","unstructured":"Barer Y, Chodick G, Cohen R, Grabarnik-John M, Ye X, Zamudio J et al (2022) Epidemiology of progressive supranuclear palsy: real world data from the second largest health plan in Israel. Brain Sci 12(9):1126","journal-title":"Brain Sci"},{"issue":"6","key":"11714_CR5","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1212\/01.WNL.0000052991.70149.68","volume":"60","author":"U Nath","year":"2003","unstructured":"Nath U, Ben-Shlomo Y, Thomson R, Lees A, Burn D (2003) Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 60(6):910\u2013916","journal-title":"Neurology"},{"issue":"6","key":"11714_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1212\/01.WNL.0000052686.97625.27","volume":"60","author":"CG Goetz","year":"2003","unstructured":"Goetz CG, Leurgans S, Lang AE, Litvan I (2003) Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology 60(6):917\u2013922","journal-title":"Neurology"},{"key":"11714_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.parkreldis.2020.04.014","volume":"73","author":"DG Coughlin","year":"2020","unstructured":"Coughlin DG, Litvan I (2020) Progressive supranuclear palsy: advances in diagnosis and management. Parkinsonism Relat Disord 73:105\u2013116. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.04.014","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"11714_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024369","volume":"6","author":"P McCrone","year":"2011","unstructured":"McCrone P, Payan CAM, Knapp M, Ludolph A, Agid Y, Leigh PN et al (2011) The economic costs of progressive supranuclear palsy and multiple system atrophy in France, Germany and the United Kingdom. PLoS\u00a0One 6(9):e24369","journal-title":"PLoS\u00a0One"},{"key":"11714_CR9","doi-asserted-by":"publisher","first-page":"S330","DOI":"10.1016\/j.jval.2020.04.1240","volume":"23","author":"Y Inuzuka","year":"2020","unstructured":"Inuzuka Y, Mellor J, Wright J, Pike J, Zabar Y (2020) PRO9 relationship between progressive supranuclear palsy and healthcare resource utilization. Value in Health 23:S330","journal-title":"Value in Health"},{"key":"11714_CR10","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/j.jval.2019.04.1645","volume":"22","author":"Y Inuzuka","year":"2019","unstructured":"Inuzuka Y, Dong S, Paradis A, Mann M, Hou Q (2019) PRO12 economic burden of progressive supranuclear palsy: health resource utilization in the United States. Value Health 22:S337","journal-title":"Value Health"},{"key":"11714_CR11","unstructured":"Statistics ICBo (2013) Characterization and classification of geographic units by the soci-economic level of the population 2008. Jerusalem, Israel"},{"issue":"3","key":"11714_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijcard.2010.08.002","volume":"152","author":"V Shalev","year":"2011","unstructured":"Shalev V, Chodick G, Goren I, Silber H, Kokia E, Heymann AD (2011) The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Int J Cardiol 152(3):345\u2013349","journal-title":"Int J Cardiol"},{"issue":"12","key":"11714_CR13","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1023\/B:EJEP.0000006635.36802.c8","volume":"18","author":"G Chodick","year":"2003","unstructured":"Chodick G, Heymann AD, Shalev V, Kookia E (2003) The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol 18(12):1143\u20131146","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"11714_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1161\/HYPERTENSIONAHA.114.03718","volume":"64","author":"D Weitzman","year":"2014","unstructured":"Weitzman D, Chodick G, Shalev V, Grossman C, Grossman E (2014) Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel. Hypertension 64(3):501\u2013507","journal-title":"Hypertension"},{"issue":"24","key":"11714_CR15","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2014.6634","volume":"311","author":"J Coresh","year":"2014","unstructured":"Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ et al (2014) Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311(24):2518\u20132531","journal-title":"JAMA"},{"issue":"1","key":"11714_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3233\/ADR-200220","volume":"4","author":"S Ben Zaken","year":"2020","unstructured":"Ben Zaken S, Radomysky Z, Koren G (2020) Association between serum magnesium levels and Alzheimer\u2019s disease or mixed dementia patients: a population-based retrospective controlled study. J Alzheimers Dis Rep 4(1):399\u2013404. https:\/\/doi.org\/10.3233\/ADR-200220","journal-title":"J Alzheimers Dis Rep"},{"key":"11714_CR17","unstructured":"Fishler Y, Chetrit A, Barchana M, Modan B (2003) Estimation of completeness of the Cancer Registry in Israel. Israel Center for Disease Control, Ministry of Health"},{"key":"11714_CR18","unstructured":"Ministry of Health I (2019) Ministry of Health Price List, 20.01.2019. https:\/\/www.gov.il\/he\/Departments\/DynamicCollectors\/moh-price-list?skip=0&moh_price_list_Date_to=2019-01-20. Accessed Feb 22, 2023 2023"},{"issue":"1","key":"11714_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1146\/annurev.publhealth.20.1.125","volume":"20","author":"P Diehr","year":"1999","unstructured":"Diehr P, Yanez D, Ash A, Hornbrook M, Lin D (1999) Methods for analyzing health care utilization and costs. Annu Rev Public Health 20(1):125\u2013144","journal-title":"Annu Rev Public Health"},{"issue":"10","key":"11714_CR20","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s00415-011-6028-7","volume":"258","author":"Y Winter","year":"2011","unstructured":"Winter Y, Stamelou M, Cabanel N, Sixel-Doering F, Eggert K, Hoeglinger GU et al (2011) Cost-of-illness in multiple system atrophy and progressive supranuclear palsy. J Neurol 258(10):1827\u20131834","journal-title":"J Neurol"},{"issue":"20","key":"11714_CR21","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1212\/WNL.0000000000004614","volume":"89","author":"JE Galvin","year":"2017","unstructured":"Galvin JE, Howard DH, Denny SS, Dickinson S, Tatton N (2017) The social and economic burden of frontotemporal degeneration. Neurology 89(20):2049\u20132056","journal-title":"Neurology"},{"key":"11714_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.571800","author":"E Viscidi","year":"2021","unstructured":"Viscidi E, Litvan I, Dam T, Juneja M, Li L, Krzywy H et al (2021) Clinical features of patients with progressive supranuclear palsy in an US insurance claims database. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2021.571800","journal-title":"Front Neurol"},{"issue":"3","key":"11714_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3233\/jad-191055","volume":"75","author":"A Wimo","year":"2020","unstructured":"Wimo A, Handels R, Winblad B, Black CM, Johansson G, Salomonsson S et al (2020) Quantifying and describing the natural history and costs of Alzheimer\u2019s disease and effects of hypothetical interventions. J Alzheimers Dis 75(3):891\u2013902. https:\/\/doi.org\/10.3233\/jad-191055","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"11714_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1600-0447.2009.01461.x","volume":"121","author":"W Quentin","year":"2010","unstructured":"Quentin W, Riedel-Heller S, Luppa M, Rudolph A, K\u00f6nig HH (2010) Cost-of-illness studies of dementia: a systematic review focusing on stage dependency of costs. Acta Psychiatr Scand 121(4):243\u2013259","journal-title":"Acta Psychiatr Scand"},{"key":"11714_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3233\/JAD-210075","volume":"81","author":"S Ikeda","year":"2021","unstructured":"Ikeda S, Mimura M, Ikeda M, Wada-Isoe K, Azuma M, Inoue S et al (2021) Economic burden of Alzheimer\u2019s disease dementia in Japan. J Alzheimers Dis 81:309\u2013319. https:\/\/doi.org\/10.3233\/JAD-210075","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"11714_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3233\/JAD-2011-110539","volume":"27","author":"JP Reese","year":"2011","unstructured":"Reese JP, He\u00dfmann P, Seeberg G, Henkel D, Hirzmann P, Rieke J et al (2011) Cost and care of patients with Alzheimer\u2019s disease: clinical predictors in German health care settings. J Alzheimers Dis 27(4):723\u2013736","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"11714_CR27","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/mds.27302","volume":"33","author":"S Weir","year":"2018","unstructured":"Weir S, Samnaliev M, Kuo TC, Tierney TS, WalleserAutiero S, Taylor RS et al (2018) Short-and long-term cost and utilization of health care resources in Parkinson\u2019s disease in the UK. Mov Disord 33(6):974\u2013981","journal-title":"Mov Disord"},{"issue":"1","key":"11714_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/mds.28265","volume":"36","author":"N Dahodwala","year":"2021","unstructured":"Dahodwala N, Li P, Jahnke J, Ladage VP, Pettit AR, Kandukuri PL et al (2021) Burden of Parkinson\u2019s disease by severity: health care costs in the US medicare population. Mov Disord 36(1):133\u2013142","journal-title":"Mov Disord"},{"issue":"4","key":"11714_CR29","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/mdc3.13458","volume":"9","author":"Y Barer","year":"2022","unstructured":"Barer Y, Gurevich T, Chodick G, Giladi N, Gross R, Cohen R et al (2022) Advanced-stage Parkinson\u2019s disease: from identification to characterization using a nationwide database. Movement Disord Clin Pract 9(4):458\u2013467","journal-title":"Movement Disord Clin Pract"},{"issue":"4","key":"11714_CR30","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3233\/jad-141134","volume":"43","author":"C Takizawa","year":"2015","unstructured":"Takizawa C, Thompson PL, van Walsem A, Faure C, Maier WC (2015) Epidemiological and economic burden of Alzheimer\u2019s disease: a systematic literature review of data across Europe and the United States of America. J Alzheimers Dis 43(4):1271\u20131284. https:\/\/doi.org\/10.3233\/jad-141134","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"11714_CR31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/1533317513488911","volume":"28","author":"BT Suehs","year":"2013","unstructured":"Suehs BT, Davis CD, Alvir J, van Amerongen D, PharmD NCP, Joshi AV et al (2013) The clinical and economic burden of newly diagnosed Alzheimer\u2019s disease in a medicare advantage population. Am J Alzheimer\u2019s Dis Other Dement 28(4):384\u2013392","journal-title":"Am J Alzheimer's Dis Other Dement"},{"issue":"11","key":"11714_CR32","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/mds.20609","volume":"20","author":"DM Huse","year":"2005","unstructured":"Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G (2005) Burden of illness in Parkinson\u2019s disease. Movement disorders: official journal of the Movement Disorder Society 20(11):1449\u20131454","journal-title":"Movement disorders: official journal of the Movement Disorder Society"},{"issue":"6","key":"11714_CR33","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1212\/WNL.0000000000012290","volume":"97","author":"AB Gandhi","year":"2021","unstructured":"Gandhi AB, Onukwugha E, Albarmawi H, Johnson A, Myers DE, Gray D et al (2021) Health Care Resource Utilization Associated With Parkinson Disease Among Medicare Beneficiaries. Neurology 97(6):e597\u2013e607","journal-title":"Neurology"},{"key":"11714_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26455","author":"M Jecmenica Lukic","year":"2022","unstructured":"Jecmenica Lukic M, Respondek G, Kurz C, Compta Y, Gelpi E, Ferguson LW et al (2022) Long-duration progressive supranuclear palsy: clinical course and pathological underpinnings. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.26455","journal-title":"Ann Neurol"},{"issue":"2","key":"11714_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.14802\/jmd.20173","volume":"14","author":"HK Park","year":"2021","unstructured":"Park HK, Ilango SD, Litvan I (2021) Environmental risk factors for progressive supranuclear palsy. J Move Disord 14(2):103","journal-title":"J Move Disord"},{"issue":"1","key":"11714_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13584-016-0073-8","volume":"5","author":"S Shahrabani","year":"2016","unstructured":"Shahrabani S, Mizrachi Y (2016) Factors affecting compliance with use of online healthcare services among adults in Israel. Israel J Health Policy Res 5(1):15. https:\/\/doi.org\/10.1186\/s13584-016-0073-8","journal-title":"Israel J Health Policy Res"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11714-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11714-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11714-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T13:03:57Z","timestamp":1689253437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11714-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["11714"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11714-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"assertion":[{"value":"23 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YB, TG, and GC declare no conflict of interest. XY, ZJ, MGJ and RC are employees of AbbVie and may own stocks of AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted in accordance with the ICH-GCP, Good Epidemiology Practices (GEP) and Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects. Study protocol was approved by the Assuta Medical Centers ethics committee (Approval Number: 0099-18-ASMC, Nov 27, 2018) and informed consent was waived, because only de-identified routinely collected data were used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent"}}]}}